T2 Biosystems’ T2Sepsis Solution with Clinical Value and Practical Application

Share Article

In this webinar, hosted by LabRoots on October 3, attendees will learn the prognostic value of the T2Sepsis Solution in the management of, and prediction of mortality in patients with candidiasis.

Patricia Muñoz, MD, PhD Division of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

The team at T2 Biosystems has arranged to have Dr. Patricia Muñoz, from the Division of Clinical Microbiology and Infectious Diseases at the Hospital General Universitario Gregorio Marañón in Madrid, present how the T2Sepsis Solution can have a positive clinical impact on septic patients by incorporating it into a sepsis protocol. Dr. Muñoz will present her data demonstrating the prognostic value of the T2Candida® Panel for the management of candidiasis patients and the T2Candida Panel as an aid to predict patient outcomes, including patients with complicated candidiasis. The webinar will also compare multiple diagnostic tools in these settings, including blood culture, Beta-D-Glucan and T2MR.

Dr. Muñoz, studied medicine in the Universidad Complutense of Madrid and did her residency in the Hospital Clínico San Carlos of Madrid, where she completed several research and clinical fellowships. At present, Dr. Muñoz is professor of medicine in clinical microbiology at the Complutense University of Madrid and Head of the infectious disease section in the Division of Clinical Microbiology and Infectious Diseases at the Hospital General Universitario Gregorio Marañón.

LabRoots will host the webinar October 3, 2017, beginning at 06:00am EDT, 12:00pm CEST. To learn more about this event, discover the continuing education credits offered, or to register for free, click here.

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit http://www.t2biosystems.com.

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website